Corvus Pharmaceuticals (CRVS) Equity Income (2021 - 2026)

Corvus Pharmaceuticals' Equity Income history runs 3 years deep, the most recent figure standing at -$1.4 million for Q4 2023.

• In Q4 2023, Equity Income rose 69.73% year-over-year to -$1.4 million; the TTM figure through Dec 2023 stood at -$5.3 million (up 47.19% YoY), while the FY2023 annual figure was -$5.3 million, up 47.19% from the prior year.
• Equity Income for Q4 2023 stood at -$1.4 million, down from -$865000.0 in the prior quarter.
• The five-year high for Equity Income was -$100000.0 in Q1 2021, with the low at -$4.6 million in Q4 2022.
• The 3-year median for Equity Income is -$1.5 million (2022), against an average of -$1.7 million.
• The sharpest annual moves came in 2022 and 2023: Equity Income plunged 941.0% in 2022, then soared 69.73% in 2023.
• Corvus Pharmaceuticals' Equity Income stood at -$2.6 million in 2021, then tumbled by 81.24% to -$4.6 million in 2022, then jumped by 69.73% to -$1.4 million in 2023.
• Business Quant data shows CRVS's Equity Income at -$1.4 million in Q4 2023, -$865000.0 in Q3 2023, and -$1.3 million in Q2 2023.